Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: A study of the Eastern Cooperative Oncology Group (EST 2292)

Cancer Journal from Scientific American

Volumn 3, Issue 5, 1997, Pages 284-288

  Wadler, Scott ^a,d   Bajaj, Rajesh ^a   Neuberg, Donna ^b   Agarwal, Venita ^a   Haynes, Hilda ^a   Benson III, Al B ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Colorectal cancer; Interferon; Ki ras; Prognosis

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; FLUOROURACIL; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; DRUG EFFICACY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; ONCOGENE K RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; GENES, RAS; HUMANS; INTERFERONS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; TREATMENT OUTCOME;

EID: 0030846104     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Parker SL, Tong T, Bolden S et al. Cancer statistics. CA Cancer J Clin 1997;47:5-27.
2. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer 1995;75 [suppl 1]:154-170.
3. Moertel CG, Fleming TR, Macdonald JS et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122: 321-326.
4. Wadler S, Schwartz EL. Antineoplastic activity of the combination of interferon and cytotoxic agents against experimental and human malignancies: a review. Cancer Res 1990;50:3473-3486.
5. Wadler S, Schwartz EL. Biologic agents as biochemical modulators: pharmacologic principles in the interaction of cytotoxic chemotherapeutic drugs and interferon. Cancer Chemother Pharmacol 1994;35:21-30.
6. Schwartz EL, Hoffman M, O'Connor C et al. Stimulation of 5-fluorouracil metabolic activation by interferon-alfa in human colon carcinoma cells. Biochem Biophys Res Commun 1991;182:1232-1239.
7. Schwartz EL, Baptiste N, O'Connor CJ et al. Potentiation of the antitumor activity of 5-fluorouracil in colon carcinoma cells by the combination of interferon and deoxyribonucleosides results from complementary results on thymidine phosphorylase. Cancer Res 1994;54:1472-1478.
8. Schwartz EL, Baptiste N, Megati S et al. 5-Ethoxy-2′-deoxyuridine, a novel pyrimidine nucleoside analog, potentiates the antitumor activity of 5-fluorouracil when used in combination with interferon. Cancer Res 1995;55:3543-3550.
9. Wadler S, Wersto R, Weinberg V et al. Interaction of fluorouracil and interferon in human colon cancer cell lines: cytotoxic and cytokinetic effects. Cancer Res 1990;50:5735-5739.
10. Wadler S, Wiernik PH. Clinical update on the combination of 5-fluorouracil and recombinant alpha-2a-interferon in the treatment of colorectal carcinoma. Semin Oncol 1990;17:16-21.
11. DuFour P, Husseini F, Dreyfus B et al. 5-Fluorouracil versus 5-fluorouracil plus α-interferon as treatment of metastatic colorectal carcinoma: a randomized study. Ann Oncol 1996;7:575-579.
12. Corfu-A Study Group. Phase III randomized study of two fluorouracil combinations with either interferon alfa-2a or leucovorin for advanced colorectal cancer. J Clin Oncol 1995;13:921-928.
13. Hill M, Norman A, Cunningham D et al. Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer. J Clin Oncol 1995;13:1297-1302.
14. Webb A, Scott-Mackie P, Cunningham D et al. The prognostic value of CEA, βhCG, AFP, CA125, CA 19-9, and c-erb B-2, βhCG immunohistochemistry in advanced colorectal cancer. Ann Oncol 1995;6:581-587.
15. Augenlicht LH. Gene structure, function and abnormalities. Cancer 1992;70[suppl]:1671-1684.
16. O'Connell MJ, Schaiad DJ, Gangu V et al. Current status of adjuvant chemotherapy for colorectal cancer. Cancer 1992;70: 1732-1739.
17. Augenlicht LH, Wadler S, Corner G et al. Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. Cancer Res 1997; 57:1769-1775.
18. Fearon ER. K-ras gene mutation as a pathogenetic and diagnostic marker in human cancer. J Natl Cancer Inst 1993;85:1978-1980.
19. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
20. Pretlow TP, Brasitus TA, Fulton NC et al. K-ras mutations in putative preneoplastic lesions in the human colon. J Natl Cancer Inst 1993;85:2004-2007.
21. Yamagata S, Muto T, Uchida Y et al. Polypoid growth and K-ras codon 12 mutation in colorectal cancer. Cancer 1995;75:953-957.
22. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319: 525-532.
23. Forrester K, Almoguera C, Han K et al. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987;327:298-303.
24. Bos J, Fearon ER, Hamilton SR et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987;327:293-297.
25. Gulbins E, Coggeshall KM, Beier G et al. Tyrosine kinase-stimulated guanine nucleotide exchange activity of vav in T-cell activation. Science 1993;260:822-825.
26. Chardin P, Camonis JH, Gale NW et al. Human sos-1: a guanine nucleotide exchange factor for ras that binds to GRB2. Science 1993;260:1338-1343.
27. Maguire J, Santoro T, Jensen P et al. Gem: an induced, immediate early protein belonging to the ras family. Science 1994;265:241-244.
28. Hall A. A biochemical function for ras - at last. Science 1994;264: 1413-1414.
29. Taniguchi T. Cytokine signaling through nonreceptor protein tyrosinekinases. Science 1995;268:251-255.
30. Darnell JE, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signalling proteins. Science 1994;264:1415-1422.
31. Silvennoinen O, Schindler C, Schlessinger J et al. Ras-independent growth factor signalling by transcription factor tyrosine phosphorylation. Science 1993;261:1736-1739.
32. Li N, Batzer A, Daly R et al. Guanine-nucleotide-releasing factor hSosI binds to Grb2 and links receptor tyrosine kinases to RAS signalling. Nature 1993;363:85-88.
33. Rozakis-Adcock M, Fernley R, Wade J et al. The SH2 and SH3 domains of mammalian Grb2 couple the EGF receptor to the ras activator mSosI. Nature 1993;363:83-85.
34. Wadler S, Lembersky B, Kirkwood J et al. Phase II trial of fluorouracil and recombinant alfa-2a-interferon in patients with advanced colorectal carcinoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 1991;9:1806-1810.
35. Rosner B: Fundamentals of Biostatistics. Boston: PWS-Kent, 1990.
36. Minamoto T, Yamashita N, Ochiai A et al. Mutant K-ras in apparently normal mucosa of colorectal cancer patients. Cancer 1995;75:1520-1526.
37. Yamashita N, Minamoto T, Ochiai A et al. Frequent and characteristic k-ras activation in aberrant crypt foci of colon: is there preference among k-ras mutants for malignant progression? Cancer 1995;75:1527-1533.
38. Losi L, Benhattar J, Costa J. Stability of k-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 1992;28A:1115-1120.
39. Finkelstein SD, Sayegh R, Bakker A et al. Determination of tumor aggressiveness in colorectal cancer by k-ras-2 analysis. Arch Surg 1993;128:526-532.
40. Finkelstein SD, Sayegh R, Christensen S et al. Genotypic classification of colorectal adenocarcinoma: biologic behavior correlates with k-ras-2 mutation type. Cancer 1993;71:3827-3838.
41. Moerkerk P, Arends JW, van Driel M et al. Type and number of ki-ras point mutations related to stage of human colorectal cancer. Cancer Res 1994;54:3376-3378.
42. Laurent-Puig P, Olschwang S, Delattre O et al. Survival and acquired genetic alterations in colorectal cancer. Gastroenterology 1992;102:1136-1141.
43. Kern S, Fearon E, Tersmette K et al. Allelic loss in colorectal carcinoma. J Am Med Assoc 1991;261:3099-3103.
44. Markowitz S, Hines JD, Lutterbaugh J et al. Mutant k-ras oncogenes in colon cancers do not predict patient's chemotherapy response or survival. Clinical Cancer Research 1995;1:441-445.
45. Kohl NE, Mosser SD, Jane deSolms S et al. Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 1993;260:1934-1937.